149 related articles for article (PubMed ID: 11679011)
1. Forced extracorporeal photopheresis (forced-ECP) in Sézary syndrome.
Kreuter A; Gambichler T; Hoffmann A; von Kobyletzki G; Altmeyer P; Hoffmann K
Int J Dermatol; 2001 Jul; 40(7):476-8. PubMed ID: 11679011
[No Abstract] [Full Text] [Related]
2. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
3. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
4. [Sézary syndrome treated with extracorporeal photopheresis: Report of one case].
Molgó M; Jaque A; Vial V; Ocqueteau M; Pereira J; Chang M; González S
Rev Med Chil; 2015 Nov; 143(11):1449-58. PubMed ID: 26757870
[TBL] [Abstract][Full Text] [Related]
5. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome.
Gao C; McCormack C; van der Weyden C; Goh MS; Campbell BA; Twigger R; Buelens O; Harrison SJ; Khoo C; Lade S; Prince HM
Blood; 2019 Oct; 134(16):1346-1350. PubMed ID: 31467061
[TBL] [Abstract][Full Text] [Related]
6. Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome.
Bouwhuis SA; el-Azhary RA; Gibson LE; McEvoy MT; Pittelkow MR
J Am Acad Dermatol; 2002 Jul; 47(1):63-7. PubMed ID: 12077583
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
8. Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.
Behle V; von Braunmühl T; Sayehli C; Gesierich A; Goebeler M; Geissinger E; Wobser M
Acta Derm Venereol; 2017 Aug; 97(8):973-975. PubMed ID: 28512672
[No Abstract] [Full Text] [Related]
9. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides.
Lewis DJ; Duvic M
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28338261
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal photopheresis in Sézary syndrome.
Russell-Jones R; Fraser-Andrews E; Spittle M; Whittaker S
Lancet; 1997 Sep; 350(9081):886. PubMed ID: 9310623
[No Abstract] [Full Text] [Related]
12. Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach.
Zackheim HS
Int J Dermatol; 2003 Jan; 42(1):53-6. PubMed ID: 12581145
[No Abstract] [Full Text] [Related]
13. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
Akilov OE
Cells; 2023 Sep; 12(18):. PubMed ID: 37759543
[TBL] [Abstract][Full Text] [Related]
14. Retinal toxic reactions following photopheresis.
Vagace JM; Gervasini G; Morais F; Benitez J; Alonso N; de Argila D; Arranz I; Bajo R
Arch Dermatol; 2007 May; 143(5):622-5. PubMed ID: 17515512
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal Photopheresis in Dermatological Diseases.
Terhaar H; Saleem M; Yusuf N
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474257
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
[TBL] [Abstract][Full Text] [Related]
18. [Extracorporeal photochemotherapy for treatment of clonal T cell proliferations].
Plumas J; Drillat P; Jacob MC; Richard MJ; Favrot MC
Bull Cancer; 2003; 90(8-9):763-70. PubMed ID: 14609767
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
20. Photopheresis in the red man or pre-Sézary syndrome.
Zachariae H; Bjerring P; Brodthagen U; Søgaard H
Dermatology; 1995; 190(2):132-5. PubMed ID: 7727834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
